Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9UMX6

UPID:
GUC1B_HUMAN

ALTERNATIVE NAMES:
Guanylate cyclase activator 1B

ALTERNATIVE UPACC:
Q9UMX6; Q9NU15

BACKGROUND:
The protein Guanylyl cyclase-activating protein 2, with alternative name Guanylate cyclase activator 1B, is instrumental in the regulation of photoreceptor recovery post-light exposure. It modulates the activity of guanylyl cyclases GUCY2D and GUCY2F based on calcium ion concentration, facilitating the transition of photoreceptors back to their dark state.

THERAPEUTIC SIGNIFICANCE:
Given its critical function in the visual cycle and its link to Retinitis pigmentosa 48, a condition marked by progressive vision loss, Guanylyl cyclase-activating protein 2 represents a promising target for developing novel treatments aimed at preserving or restoring vision.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.